# Amphastar Pharmaceuticals, Inc.: overview

AMPH · Nasdaq · CIK 1297184 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/amph.md) · [Financials](/companies/amph/financials.md) · [Filings](/companies/amph/filings.md) · [Insiders](/companies/amph/insiders.md)

Latest reported revenue: [$183.9m](/filings/0001297184-26-000047.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001297184-26-000047).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [191](/filings/0001297184-25-000064.md) | [187 d](/filings/0001297184-26-000009.md) | [171](/filings/0001297184-26-000033.md) | [174](/filings/0001297184-26-000047.md) | [192](/filings/0001297184-25-000064.md) | [183 d](/filings/0001297184-26-000009.md) | [171](/filings/0001297184-26-000033.md) | [184](/filings/0001297184-26-000047.md) |
| Gross margin | % | [53.3%](/filings/0001297184-25-000064.md) | [46.5% d](/filings/0001297184-26-000009.md) | [50.0%](/filings/0001297184-26-000033.md) | [49.6%](/filings/0001297184-26-000047.md) | [51.4%](/filings/0001297184-25-000064.md) | [46.8% d](/filings/0001297184-26-000009.md) | [41.1%](/filings/0001297184-26-000033.md) | [50.8%](/filings/0001297184-26-000047.md) |
| Operating margin | % | [29.8%](/filings/0001297184-25-000064.md) | [24.2% d](/filings/0001297184-26-000009.md) | [21.9%](/filings/0001297184-26-000033.md) | [24.2%](/filings/0001297184-26-000047.md) | [13.2%](/filings/0001297184-25-000064.md) | [19.4% d](/filings/0001297184-26-000009.md) | [8.0%](/filings/0001297184-26-000033.md) | [21.6%](/filings/0001297184-26-000047.md) |
| Net margin | % | [21.1%](/filings/0001297184-25-000064.md) | [20.4% d](/filings/0001297184-26-000009.md) | [14.8%](/filings/0001297184-26-000047.md) | [17.8%](/filings/0001297184-26-000047.md) | [9.0%](/filings/0001297184-25-000064.md) | [13.3% d](/filings/0001297184-26-000009.md) | [3.8%](/filings/0001297184-26-000047.md) | [16.5%](/filings/0001297184-26-000047.md) |
| Diluted EPS | $ per share | [0.78](/filings/0001297184-25-000064.md) | not reported | [0.51](/filings/0001297184-26-000033.md) | [0.64](/filings/0001297184-26-000047.md) | [0.37](/filings/0001297184-25-000064.md) | not reported | [0.14](/filings/0001297184-26-000033.md) | [0.67](/filings/0001297184-26-000047.md) |
| Free cash flow | $m | [46.2 d](/filings/0001297184-25-000064.md) | [16.6 d](/filings/0001297184-26-000009.md) | [24.4](/filings/0001297184-26-000033.md) | [25.0 d](/filings/0001297184-26-000047.md) | [47.2 d](/filings/0001297184-25-000064.md) | [24.6 d](/filings/0001297184-26-000009.md) | [38.3](/filings/0001297184-26-000033.md) | [42.7 d](/filings/0001297184-26-000047.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [438](/filings/0001297184-24-000009.md) | [499](/filings/0001297184-25-000008.md) | [644](/filings/0001297184-26-000009.md) | [732](/filings/0001297184-26-000009.md) | [720](/filings/0001297184-26-000009.md) |
| Gross margin | % | [45.6%](/filings/0001297184-24-000009.md) | [49.9%](/filings/0001297184-25-000008.md) | [54.5%](/filings/0001297184-26-000009.md) | [51.1%](/filings/0001297184-26-000009.md) | [49.5%](/filings/0001297184-26-000009.md) |
| Operating margin | % | [16.0%](/filings/0001297184-24-000009.md) | [21.5%](/filings/0001297184-25-000008.md) | [30.6%](/filings/0001297184-26-000009.md) | [28.1%](/filings/0001297184-26-000009.md) | [19.5%](/filings/0001297184-26-000009.md) |
| Net margin | % | [14.2%](/filings/0001297184-24-000009.md) | [18.3%](/filings/0001297184-25-000008.md) | [21.3%](/filings/0001297184-26-000009.md) | [21.8%](/filings/0001297184-26-000009.md) | [13.6%](/filings/0001297184-26-000009.md) |
| Diluted EPS | $ per share | [1.25](/filings/0001297184-24-000009.md) | [1.74](/filings/0001297184-25-000008.md) | [2.60](/filings/0001297184-26-000009.md) | [3.06](/filings/0001297184-26-000009.md) | [2.03](/filings/0001297184-26-000009.md) |
| Free cash flow | $m | [70.5](/filings/0001297184-24-000009.md) | [65.1](/filings/0001297184-25-000008.md) | [145](/filings/0001297184-26-000009.md) | [172](/filings/0001297184-26-000009.md) | [121](/filings/0001297184-26-000009.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/amph/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $105.4m | 5,224,934 |  | Reduced −196,409 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $46.5m | 2,305,107 |  | Added +277,160 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $33.1m | 1,642,126 |  | Added +34,611 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $29.9m | 1,481,952 |  | Reduced −61,703 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $23.7m | 1,176,626 |  | Added +159,088 |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $21.5m | 1,066,322 |  | Added +40,682 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $19.6m | 969,840 |  | Reduced −6,810 |
| [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $19.2m | 949,238 |  | Reduced −445,901 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $17.9m | 887,048 |  | Added +221,506 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $16.3m | 809,568 |  | Added +21,752 |

## Recent filings

[All 938 filings](/companies/amph/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 16:50 ET | [10-Q](/filings/0001297184-26-000047.md) | Quarterly report, period 2026-06-30 | 0001297184-26-000047 |
| 2026-08-06 | 16:32 ET | [8-K](/filings/0001297184-26-000045.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001297184-26-000045 |
| 2026-07-13 | 06:01 ET | [8-K](/filings/0001104659-26-082772.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-082772 |
| 2026-07-08 | 20:03 ET | [8-K](/filings/0001297184-26-000041.md) | 8.01 Other events | 0001297184-26-000041 |
| 2026-06-03 | 16:15 ET | [8-K](/filings/0001297184-26-000038.md) | 5.07 Shareholder vote results | 0001297184-26-000038 |
| 2026-05-07 | 16:48 ET | [10-Q](/filings/0001297184-26-000033.md) | Quarterly report, period 2026-03-31 | 0001297184-26-000033 |
| 2026-05-07 | 16:22 ET | [8-K](/filings/0001297184-26-000031.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001297184-26-000031 |
| 2026-04-13 | 16:18 ET | [DEF 14A](/filings/0001297184-26-000023.md) | Proxy statement, period 2026-06-01 | 0001297184-26-000023 |
| 2026-03-16 | 06:00 ET | [8-K](/filings/0001104659-26-027814.md) | 8.01 Other events | 0001104659-26-027814 |
| 2026-03-06 | 16:17 ET | [8-K](/filings/0001297184-26-000015.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001297184-26-000015 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001297184-26-000009.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/2d5deaee-e396-4b8e-919c-7f69b8a8c9a9)

## About the filer

- CIK: 1297184
- Tickers: AMPH
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.